Gain Therapeutics initiated with an Outperform at Scotiabank

Scotiabank initiated coverage of Gain Therapeutics (GANX) with an Outperform rating and $12 price target Gain’s GT-02287 is potential blockbuster drug in Phase 1b that could be a disease-modifying treatment for Parkinson’s disease, the analyst tells investors in a research note. If interim analysis of the trial data set to be provided in Q2 are positive, this would be a major value inflection point for Gain, helping to establish proof of concept for targeting Glucocerebrosidase to treat PD, the firm says.